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mTORParkinson's disease (PD) is the second most common neurodegenerative disorder. Although the causes of PD are
still not understood, aging is a predisposing factor andmetabolic stress seems to be a common trigger. Interestingly,
the response to stress conditions and quality controlmechanisms is impaired in PD, aswell as in other neurodegen-
erative disorders. Downregulation of rRNA transcription is one major strategy to maintain cellular homeostasis
under stress conditions, as it limits energy consumption in disadvantageous circumstances. Altered rRNA transcrip-
tion and disruption of nucleolar integrity are associated with neurodegenerative disorders, and with aging.
Nucleolar stress can be triggered by genetic and epigenetic factors, and by speciﬁc signaling mechanisms,
that are altered in neurodegenerative disorders. The consequences of neuronal nucleolar stress seem to
depend on p53 function, the mammalian target of rapamycin (mTOR) activity and deregulation of protein
translation. In this review, we will summarize ﬁndings identifying an emerging role of nucleolar stress
for the onset and progression of in particular PD. Emphasis is given to similarities in molecular causes
and consequences of nucleolar stress in other neurodegenerative disorders. The mechanisms by which
nucleolar stress participates in PD could help identify novel risk factors, and develop new therapeutic strategies
to slow down the progressive loss of neurons in neurodegenerative diseases. This article is part of a Special Issue
entitled: Role of the Nucleolus in Human Disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Neurodegenerative disorders are chronic diseases, characterized by
the progressive loss of speciﬁc neurons in the central or peripheral
nervous system. This deﬁnition is however an oversimpliﬁcation of
complexdiseases forwhichup to now there is still no cure and therapies
aremostly symptomatic [1].While distinct populations of neurons seem
to be primarily lost in distinct diseases, various symptoms, neurodegen-
erative triggers and pathways may overlap. For example, Alzheimer's
disease (AD), which causes dementia, is characterized by degeneration
of cortical and hippocampal neurons [2]. Major movement-relatedotrophic lateral sclerosis; DA,
ukaryotic initiation factor 4E
2, leucine-rich repeat kinase 2;
SNs, medium spiny neurons;
HDA, 6-hydroxydopamine; PD,
phosphatase and tensin homo-
; SMA, spinal muscle atrophy;
, transcription initiation factor-
and TNF receptor-associated
e Nucleolus in Human Disease.
d Cell Biology, Department of
er Feld 307, 69120 Heidelberg,
o).
ights reserved.symptoms of Parkinson's disease (PD) are associated with the loss of a
particular subpopulation of dopaminergic (DA) midbrain neurons [3];
nevertheless other neurons are also affected in PD and a subpopulation
of PD patients (ca. 30%) shows additional dementia symptoms [3–5].
Familial forms leading toMendelian inheritance of disease are described
for both PD and AD, and certain genetic loci have been identiﬁed that
increase the risk for idiopathic AD or PD [5]. Furthermore, converging
disease mechanisms are evident downstream of the causes or trigger
factors that primarily initiate or increase the risk of each disease [6]. In
addition even in clearly inherited monogenic neurodegenerative
diseases, such as Huntington's disease (HD), unknown predisposing
and environmental factorsmodify onset and progression of the selective
loss of striatal neurons, implying the existence of additional risk or trig-
ger factors (genetic and not) [7]. This is also true for the selective degen-
eration of distinct motor-neuron populations in amyotrophic lateral
sclerosis (ALS) or spinal muscle atrophy (SMA), where idiopathic as
well as inherited forms are described [8,9]. These aspects should be
taken into account to fully understand distinct and common disease
mechanisms and to design effective neuroprotective treatments.
Ideally one would like to identify the individual disease cause as well
as its molecular pathomechanism and utilize this as a target for a causal
therapy of a neurodegenerative disease. However this strategy has not
been too successful in neurodegenerative research so far.Most likely be-
cause the situation is much more complex — rather a neurodegenera-
tive disease is caused by a complex interplay of variable genetic and
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for a disease (e.g. in HD the expanded CAG repeat in the huntingtin
gene), the question of when and why its effects become threatening is
still unanswered.
Another approach for developing novel therapeutic treatments is
based on the identiﬁcation of downstream neurodegenerative path-
ways that are common in distinct neurodegenerative diseases. Indeed,
such common neurodegenerative determinants and pathways have
been identiﬁed in the last years: in particular cellular and metabolic
stress, such as oxidative stress, proteasomal stress, and nucleolar stress
seem to be common events in neurodegenerative disorders [12–14].
Nucleolar stress is an emerging component of the degenerative process,
caused by impaired rRNA transcription and altered nucleolar integrity
[15]. rRNA transcription itself strongly depends on cellular stress and
it is controlled by a combination of genetic and epigenetic factors [16].
rRNA transcription is epigenetically regulated during aging as well as
in neurodegenerative diseases like AD and HD e.g. by hypermethylation
of rDNA promoter or post-translational modiﬁcations of RNA Polymer-
ase I co-factors [17–20]. Similarﬁndings in PD are still missing, however
in light of the emerging role of epigenetics in PD pathogenesis [21,22], it
is tempting to hypothesize an association with PD as well.
This review aims at presenting evidence for a role of nucleolar stress
in PD and other neurodegenerative diseases. We will summarize in
particular, mechanisms by which nucleolar stress could play a role in
PD progression. These mechanisms include p53-dependent programs,
as well as the mammalian/mechanistic target of rapamycin (mTOR)
signaling. P53 is a tumor suppressor gene and transcription factor, con-
trolling cell-cycle, apoptosis and genomic stability [23], while mTOR is a
phosphatidylinositol 3-kinase-related kinase regulating cell prolifera-
tion, protein and RNA synthesis as well as cell survival [24]. Finally,
we will summarize evidence that dysregulation of protein translation
may cause neurodegenerative disorders including PD.
2. Parkinson's disease and nucleolar stress
PD is the second most common neurodegenerative disorder; it is
known to not only cause abnormal motor function (bradykinesia,
resting tremor, rigidity and postural instability), but also impair
autonomic functions and cognition [3]. Most motor symptoms of PD
are caused by a progressive loss of DA midbrain neurons, in particular
within the Substantia nigra (SN), while DA neurons within the ventral
tegmental area (VTA) remain largely unaffected [25,26]. Approximately
10–20% of PD is ascribed to familial inherited mutations in PARK1–13
genes, but PD is generally considered a sporadic disease inﬂuenced by
genetic and environmental risk factors [27–30].
PD shares with other neurodegenerative disease deﬁcits inmitochon-
drial and proteasomal/lysosomal function, mechanisms regulating pro-
tein quality control, stress response and cell metabolism [31,32].
Proteasomal and mitochondrial dysfunction is either caused by environ-
mental factors, such as mitochondrial complex I blockers (e.g. rotenone,
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/MPTP, paraquat), or
proteasomal inhibitors (e.g. epoxomycin), or by genetic factors— likemu-
tations or variations in PARK genes [10,27,33,34]. Given the relatively late
onset (65–85 years) and slow progression of most idiopathic PD cases,
identiﬁcationofmolecularmechanisms responsible formaintaining cellu-
lar homeostasis aswell as compensatorymechanismsmight allow a ther-
apeutic intervention in early disease stages, to slowdownor even stop the
progressive loss of DA neurons in the course of the disease [35].
Nucleolar activity and integrity are tightly linked to the cellularwell-
being and metabolic state [16]. The nucleolus hosts several hundreds of
proteins that are shuttled between different cellular compartments
[36]. Crucial regulatory functions can be altered by nucleolar disruption
and the release of nucleolar proteins to the nucleoplasm [36]. The
dynamic retention/release of nucleolar proteins provides a control of
cellular functions, including stress response [37]. For example, the
nucleoplasmic release of ribosomal proteins upon inhibition of rRNAsynthesis affects p53 turnover with dramatic consequences for cell
proliferation, survival and stress response [37]. It seems obvious on
the one hand that cells need proper nucleolar activity and protein
synthesis to function correctly. On the other hand, down-regulation of
rRNA transcription in response to stress conditions allows cells to limit
energy expenditure and to keep conducting their functions under
minimal regime [16]. However, protracted inhibition of rRNA synthesis
results in severe cellular damage and cell death [37].
The nucleolar-dependent mechanisms that are responsible for the
switch from life to death are still poorly investigated but they could
allow a better understanding on howneuronsmanage to resist a neuro-
degenerative process under stress. In this context it is of particular inter-
est that in most common neurodegenerative diseases, neurons are not
equally affected by the disease process but rather display a so-called
differential vulnerability of distinct neuronal populations to the neuro-
degenerative process, as illustrated for PD [1].
3. Increased nucleolar stress is present in PD and other
neurodegenerative disorders
Decreased rRNA synthesis and nucleolar disintegration have been
reported in a variety of neurodegenerative disorders [14]. In PD brain
autopsies altered nucleolar function and morphology have been de-
scribed in DA neurons [38]. Initial data show that nucleolar volume in
DA neurons is decreased in PD subjects and this is inversely correlated
with the disease duration, suggesting metabolic alterations in these
neurons [39,40]. Indeed reduced nucleolar volume has been associ-
ated with reduced RNA synthesis [41].
Asmentioned, age is themost prominent risk-factor for PD. Interest-
ingly, 18S rRNA levels decrease with aging in humans and mice [42,43],
and an increased nucleolar fragmentation with age is described [44].
Synthesis of rRNA is downregulated in DA neurons in a pharmacological
mouse model of PD based on injection of MPTP, and it is associated
with disruption of nucleolar integrity [38]. More recently, decreased
nucleolar volumehas been reported in the partial unilateral intrastriatal
6-hydroxydopamine (6-OHDA) oxidative stress rat model of PD [45].
Interestingly, in AD, there is also a signiﬁcant atrophy of the nucleoli
[46]; on the other side nucleolar hypertrophy has been linked to neuro-
toxic β-amyloid deposits and Aβ plaques in the hippocampus of asymp-
tomatic AD subjects [46]. Reduced nucleolar volume and reduced RNA
synthesis may reﬂect neuronal atrophy and in general a suffering neu-
ron, however reduced or altered nucleolar activity could in addition
play an active role in the disease progression.
Nucleolar proteins regulating rRNA synthesis and ribosome biogen-
esis could contribute to the pathophysiological mechanisms of different
neurodegenerative diseases, e.g. by mutations or agents affecting
their expression and activity [18,47–55]. DNA damage, a hallmark of
neurodegenerative diseases, results in translocation to the nucleoplasm
of nucleophosmin (NPM), a multifunctional protein with chaperone
activity [56]. Although NPM role in neurodegeneration is not fully char-
acterized, kainic acid-induced neurotoxicity promotes downregulation
of NPM in rat hippocampus [47]. In turn, NPM overexpression is
neuroprotective, at least in cellular models [47]. A pathogenic role
in neurodegeneration has been clearly reported for nucleolin.
Nucleolin is a phosphoprotein that interacts with mutant RNAs in
polyglutaminopathies like HD, resulting in its reduced binding to rRNA
promoters, reduced rRNA transcription and increased nucleolar stress
[18,49]. Interestingly, nucleolin is downregulated in SN tissues from
PD subjects and in a DA cellular model of PD upon treatment with rote-
none [48]. Nucleolin associates with α-synuclein (PARK1/PARK4) and
DJ-1 (PARK7), two genes whose mutations can cause familial forms of
PD [50]. The impact of nucleolin on rRNA transcription has not been
addressed in this model; nevertheless nucleolin overexpression is
neuroprotective and its downregulation promotes neuronal death in a
PD cellular model [48] and in various models of polyglutaminopathies
[18,49]. Another example is the ribonuclease angiogenin that
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rRNA transcription [51]. Angiogenin variants are frequent in PD and
ALS and could be predisposing factors in both diseases [57]. Notably,
angiogenin is downregulated in transgenic mice overexpressing
human wildtype α-synuclein [58]. Angiogenin knockdown leads to
cell death while its overexpression promotes neuronal survival in
models of ALS [59]. Similarly angiogenin reduces cell death in cellular
PD models based on MPP+ and rotenone treatment [53]. However in a
recent in vivo study in the MPTPmouse model of PD where angiogenin
was overexpressed by stereotactic injection in DA neurons, these neu-
rons were not protected from degeneration [60]. Nevertheless it is not
only the level of angiogenin expression but also its localization that
plays a role in the regulation of neuronal survival [61]. Indeed it has
been shown that angiogenin promotes rRNA transcription under per-
missive growth conditions: under stress conditions angiogenin translo-
cates to the cytoplasm reducing protein translation and increasing cell
survival [61]. Survival motor neuron (SMN) protein is mutated in SMA
[55]. Interestingly wild-type SMN is associated in a complex with NPM
and nucleolin [62]. However in SMA patient-derived ﬁbroblasts mutant
SMN is not associated with NPM and nucleolin [62]. Future research
should explain whether altered distribution of mutant SMN plays a
role in the pathogenesis of SMA.
The role of relocalization of nucleolar proteins in neuronal survival
has been demonstrated in other systems. Increased pre-rRNA biogene-
sis and reduced mature 18S and 28S rRNA have been recently reported
in a cellular proteasomal inhibition model of PD [63]. In the nucleolus,
TRAF and TNF receptor-associated protein (TTRAP) is a multifunctional
protein that can control levels of rRNA precursor and processing inter-
mediates [64,65]. In response to proteasome inhibition, TTRAP accumu-
lates in nucleolar cavities and regulates rRNA processing [65]. Silencing
TTRAP expression causes alterations in rRNA biogenesis during protea-
some impairment, with a decrease of pre-rRNA and an accumulation
of processing intermediates [65]. Notably the PD associated mutant
protein DJ-1 L166P that results in a misfolded protein and aggregate
formation impairs TTRAP localization in the nucleolar cavities
and rRNA transcription [63]. Hence, these studies show that impaired
nucleolar function may be speciﬁcally triggered by a disease-
associated mutant protein and suggest a novel pathophysiological
mechanism in PD. Interestingly, this mechanism is similar to that iden-
tiﬁed in polyglutaminopathies, like HD, in which mutant mRNAs inter-
fere with RNA polymerase I transcription [18,49]. Noteworthy, these
ﬁndings indicate that inhibition of rRNA transcription can be a primary
event of the degenerative process.
4. Animal models of induced nucleolar stress
Although nucleolar stress appears to be a common component of
neurodegenerative disorders [14,15], only recently the cellular and
molecular consequences of impaired rRNA synthesis and nucleolar dis-
ruption have been systematically explored in the nervous system.
Mouse models in which nucleolar stress is induced in speciﬁc neuronal
populations at a deﬁned time-point have been generated, based on theTable 1
Temporal link between nucleolar stress, p53, oxidative damage and cell death in distinct TIF-IA
Cre recombinase activity Nucleolar stress Inc
Neural and glial progenitors (E9.5) E11.5 E11
Adult hippocampal neuronsc 1 month 3 m
DA neurons (E13.5) E18.5 E18
Adult DA neuronsc 2 weeks 2 w
Dopaminoceptive neurons (E16.5) 1 month 2 m
a Analyzed by activated caspase-3.
b Analyzed by Terminal deoxynucleotydil transferase dUTP end labeling, TUNEL assay.
c Induced by tamoxifen injection in 2-month old mice and analyzed at the indicated stages.
d Analyzed by neuronal loss.conditional ablation of the transcription factor TIF-IA [66]. TIF-IA is es-
sential for the recruitment of RNA polymerase I to the rRNA promoters
[66]. TIF-IA activity is tightly regulated by mitogenic signals, growth
stimuli, oxidative stress, cellular energy status and ER stress, and it rep-
resents an essential crossroad in the control of rRNA transcription under
stress conditions [41,67,68]. Therefore conditional ablation of TIF-IA by
the Cre-loxP system is a convenient tool to mimic nucleolar stress in
speciﬁc cellular and developmental/aging contexts (Table 1). Condition-
al TIF-IA ablation in embryonic neural progenitors using the Nestin-Cre
transgenic line leads to rapid loss of developing neurons starting E11.5
by p53-dependent apoptosis and anencephaly [69]. On the contrary,
cell-speciﬁc TIF-IA ablation in distinct postmitotic neurons results in
their slowly progressive degeneration; in addition these studies reveal
that hippocampal, DA and dopaminoceptive neurons can survive
for several months under nucleolar stress [38,69–71]. This slow
progression allows the analysis of the sequence of events triggered by
nucleolar stress in distinct neuronal populations (Table 1). Interestingly,
DA-speciﬁc TIF-IA ablation results in mutant mice, characterized by be-
havioral and cellular features reminiscent of PD, including progressive
and preferential loss of DA neurons in the SN vs VTA DA neurons, as
well as marked behavioral deﬁciencies (slowness of movement, gait
and posture disturbances) [38]. Importantly, selective impairment of
nucleolar activity at the age of twomonths in DA neurons leads tomito-
chondrial dysfunction and increased oxidative damage, characteristics
shared by various neurodegenerative diseases, such as PD, HD, AD and
ALS, and summarized in Table 2. This Table shows mechanisms either
“associated” with a disease (meaning that they are described in
human and/or animal models), or “directly related” to a disease (mean-
ing that they are proven to be caused/triggered bymutant RNAs or pro-
teins based on experimental evidence). We refer to recent reviews and
original articles for detailed information (see Table 2). Interestingly,
most of the mechanisms involved in these listed neurodegenerative
diseases [31] are also described in conditional TIF-IA knock-out mice
(cKO), in particular DA and striatal speciﬁc models (Table 2).
How nucleolar stress could lead to mitochondrial dysfunction, in-
creased oxidative damage and ﬁnally neurodegeneration is discussed
in the next paragraph.
5. Nucleolar stress can induce mitochondrial dysfunction and
neurodegeneration in PD and other neurodegenerative diseases:
role of mTOR
Abnormalities in protein synthesis are common to PD and may be
related to impaired Akt-mTOR signaling [72–74]. First evidence that
nucleolar stress also leads to downregulation of mTOR was indeed de-
rived from the DA-speciﬁc inducible TIF-IA knock-out mice [38]. Recent
analysis of conditional mutant mice lacking TIF-IA in striatal medium
spiny neurons (MSNs) revealed that mTOR activity is inhibited also in
these neurons and that p53 increases the phosphatase PTEN (phospha-
tase and tensin homolog deleted on chromosome 10), a well-known
inhibitor of the mTOR signaling. Remarkably, a mouse model of
spinocerebellar ataxia characterized by increased DNA damage andconditional mutant mice.
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affected cerebellum [75]. Moreover, mTOR inhibition inMSNs promotes
autophagy highlighting an initial neuroprotective effect triggered by
nucleolar stress [70]. Further analysis of the conditional mutant mice
lacking both TIF-IA and PTEN indicates that this neuroprotective effect
could depend on PTEN [70]. In fact the loss of TIF-IA and PTEN results
in upregulation of mTOR, block of autophagy and accelerated neuronal
death [70]. This is of particular importance as altered autophagy pro-
vides another trigger factor of PD [76,77]. Nevertheless, absence of
PTEN and activation of themTOR pathway are partially neuroprotective
in adult DA neurons lacking TIF-IA [78]. Indeed double mutants lacking
both TIF-IA and PTEN show improved motor performance on the
rotarod test in comparison to TIF-IA single mutants [78]. These distinct
ﬁndings for the role of PTEN and mTOR in MSN- or DA-speciﬁc
postmitotic neurons under nucleolar stress point to a context- and
time-speciﬁc role of the mTOR pathway for neuronal survival.
The analysis of the conditional TIF-IA models indicates a dual role of
that nucleolar stress: initially it could trigger a neuroprotective defense
response, in particular by inducing autophagy [70]. However, enduring
nucleolar stress also leads to impaired mitochondrial function and in-
creased oxidative stress, and ultimately slowly progressing neuronal
death [38,70]. In this view, these ﬁndings suggest that the identiﬁcation
of acute as well as chronic regulators and downstream effectors of
impaired nucleolar function can help to better understand disease
progression and might open avenues for the development of novel
neuroprotective therapeutic strategies.
6. Nucleolar stress can induce mitochondrial dysfunction and
neurodegeneration in PD: role of p53
Besides mTOR pathways, it is well known that the nucleolus trans-
mits cellular stress signals to the p53 pathways [79]. Upon disruption
of the nucleolus, several ribosomal proteins (RPs) are released into the
nucleoplasm and bind to the E3 ubiquitin ligase Mdm2 [37]. Mdm2
promotes p53 degradation, but when bound to RPs it does not function
correctly, leading to accumulation of p53 with context-dependent con-
sequences on cell viability and metabolism [80]. Inhibition of p53 has
been shown to be neuroprotective in the MPTP model of PD [81]. Inter-
estingly p53 activity is linked to several geneswith a causative role in PD
[82]. For example, in response to oxidative stress, p53 transcriptionally
upregulates the ubiquitin ligase parkin (PARK2) and promotes mito-
chondrial respiration and antioxidant defense [83]. In turn parkin
downregulates p53 transcription limiting the negative consequences
of its increased activity [84]. These results show that parkin can function
also as transcriptional repressor by interacting with p53 promoter.
However mutant parkin loses this neuroprotective function, offering
an explanation how this mutation could result in p53 induction and
apoptotic cell death [84,85]. Interestingly parkin positively regulates
another gene with a causative role in PD DJ-1 (PARK7) by inhibiting
p53; again this neuroprotective function is lost by mutant parkin [86].
These ﬁndings link these (and additional) factors to a complex signaling
network, thatmight be jointly altered in a cell-speciﬁc fashion in neuro-
degenerative disease, like PD.
To add complexity, p53 also plays a role in the downregulation of
mTOR activity, observed in both DA and dopaminoceptive MSNs upon
nucleolar stress [38,70]. In Drosophila, mutations in PINK1 (PARK6),
parkin (PARK2) or leucine-rich repeat kinase 2 (LRRK2/PARK8) genes
result in dysregulated translation, increased sensitivity to oxidative
stress and age-related loss of DA neurons [87,88]. This phenotype is
linked to abnormal phosphorylation of the eukaryotic initiation factor
4E (eIF4E)-binding protein (4E-BP1) [88]. Hypophosphorylation of 4E-
BP1 is required for its function as a repressor of protein translation
[24]. By phosphorylating 4E-BP1 mTOR promotes protein translation
[24]. Interestingly in these Drosophila mutants inhibition of TOR by
rapamycin represses protein translation and prolong neuronal survival
[87,88]. In line with these results, PINK1 (PARK6) knock-out mice
795R. Parlato, B. Liss / Biochimica et Biophysica Acta 1842 (2014) 791–797show reducedmTOR activity and decreased levels of phosphorylated ri-
bosomal S6 protein, another target of mTOR [89]. However 4E-BP1 has
not been conﬁrmed as a substrate of LRRK2 in mammalian brain and
it is not clear whether mutant LRRK2 participates to the abnormal
protein translation observed in PD [90]. Nevertheless other regulators
of protein translation are emerging in PD in particular variants in the
eukaryotic translation initiation factor 4-gamma 1 gene (EIF4G1) are
associated with familial PD forms [91]. It is tempting to speculate that
deﬁcits of protein translation are common to several neurodegenerative
diseases. As strongly indicated by a recent study, e.g. increased phos-
phorylation of α-subunit of eukaryotic translation initiation factor 2
(eIF2α) reduces protein translation in PD mouse models [92].
7. Open questions and perspectives
This review summarizes a series of intriguing studies that link PD to
alterations in nucleolar function, and it offers mechanisms by which
nucleolar stress could lead to selective neurodegeneration. However,
in particular the selective neurodegeneration of distinct neuronal popu-
lations, a hallmark of all neurodegenerative diseases, needs further
investigation.
The animal models based on inducible nucleolar stress at a deﬁned
time-point in speciﬁc neuronal populations offer one novel and unique
tool to further study functional and molecular consequences of nucleo-
lar stress in different contexts, and to identify central regulatory — and
potentially neuroprotective pathways [38,69,70,78]. Interestingly, the
characteristic differential vulnerability of DA midbrain subpopulations
observed in PD and its animalmodels (SN versus VTA) [93,94], is indeed
present in the DA-speciﬁc TIF-IA models, despite induction of nucleolar
stress and increased p53 also in all DA midbrain neurons [38]. This
ﬁnding points to an additional intrinsic factor that renders SN DA
neurons particularly vulnerable to nucleolar stress and other neurode-
generative triggers. Another explanation could be that TIF-IA expression
and function might be lower in more resistant (e.g. VTA DA) neurons
compared to highly vulnerable (e.g. SN DA) neurons. In this context, it
is interesting to note that neurotrophins like BDNF control TIF-IA [95].
However, up to now a cell-speciﬁc analysis of neuronal TIF-IA expres-
sion in health, aging, and disease is missing.
Other open questions are related to the age- or disease-stage-
speciﬁc effects of nucleolar stress and the neuroprotective role of
rRNA synthesis. It would be important to establish at what levels nucle-
olar stressmight trigger protective responses, ormight become deleteri-
ous to a certain neuron, and what factors could contribute to those
nucleolar stress levels. For example, do PARK genemutations chronically
alter nucleolar activity and integrity selectively in the most vulnerable
population of SN DA neurons? And can reduction of nucleolar stress
reduce the distinct phenotypes of the PARK mouse models? To start
answering to these questions the cellular and molecular consequences
of nucleolar stress in combination with genetic mutations underlying
PD should be addressed. These studies could open avenues to identify
novel disease pathways, and also to novel therapeutic approaches.
However, to reach that desired goal, much further research and insight
into the emerging converging role of nucleolar dysfunction – in interplay
with other environmental and genetic factors and disease pathways – in
PD and other neurodegenerative disease are essential.
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